Literature DB >> 8086912

Cancer prevention in primary care. Current trends and some prospects for the future--II.

J Austoker1.   

Abstract

Cancer control encompasses the whole spectrum from prevention and early diagnosis to treatment and palliation. The key to the future of cancer control will be to establish multidisciplinary approaches to each type of cancer across this spectrum. For primary prevention this requires some understanding of the causes of each cancer. Although understanding of the aetiology of cancer has greatly improved, prospects for the primary prevention of many common cancers remain remote. Other approaches currently under evaluation include chemoprevention and the use of biomarkers (discussed last week). The identification of predisposing genes for some of the common cancers may have a considerable impact on the ability to recognise those at risk. Overall, however, mortality trends indicate that reduction of smoking remains the main priority for cancer prevention in the United Kingdom. For primary care teams, brief interventions to reduce smoking are likely to achieve the greatest benefit. This should be seen as part of broader policies aimed at achieving change in the whole population. The government must acknowledge its major responsibility to cancer prevention by banning all forms of advertising and promotion of tobacco.

Entities:  

Mesh:

Year:  1994        PMID: 8086912      PMCID: PMC2542724          DOI: 10.1136/bmj.309.6953.517

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

1.  Medical audit, cancer registration, and survival in ovarian cancer.

Authors:  C R Gillis; D J Hole; R M Still; J Davis; S B Kaye
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

2.  Survival of patients with cancer.

Authors:  C A Stiller
Journal:  BMJ       Date:  1989-10-28

3.  Health and behavioural change: some lay perspectives.

Authors:  S M Hunt; M Macleod
Journal:  Community Med       Date:  1987-02

4.  Involvement of the primary health care team in coronary heart disease prevention.

Authors:  M Calnan; S Cant; S Williams; A Killoran
Journal:  Br J Gen Pract       Date:  1994-05       Impact factor: 5.386

5.  Inherited breast and ovarian cancer. What are the risks? What are the choices?

Authors:  M C King; S Rowell; S M Love
Journal:  JAMA       Date:  1993-04-21       Impact factor: 56.272

6.  Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival.

Authors:  C S McArdle; D Hole
Journal:  BMJ       Date:  1991-06-22

7.  Leukaemia incidence after iodine-131 exposure.

Authors:  P Hall; J D Boice; G Berg; G Bjelkengren; U B Ericsson; A Hallquist; M Lidberg; G Lundell; A Mattsson; J Tennvall
Journal:  Lancet       Date:  1992-07-04       Impact factor: 79.321

8.  Prospects for the chemoprevention of breast cancer.

Authors:  M Baum; Y Ziv; A Colletta
Journal:  Br Med Bull       Date:  1991-04       Impact factor: 4.291

Review 9.  Biomarker intermediate endpoints and cancer prevention.

Authors:  F L Meyskens
Journal:  J Natl Cancer Inst Monogr       Date:  1992

10.  Mortality from tobacco in developed countries: indirect estimation from national vital statistics.

Authors:  R Peto; A D Lopez; J Boreham; M Thun; C Heath
Journal:  Lancet       Date:  1992-05-23       Impact factor: 79.321

View more
  3 in total

Review 1.  Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study.

Authors:  S Kumar; M Gantley
Journal:  BMJ       Date:  1999-11-27

Review 2.  Apigenin: a promising molecule for cancer prevention.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Pharm Res       Date:  2010-03-20       Impact factor: 4.200

3.  Referrals of women with a family history of breast cancer from primary care to cancer genetics services in South East Scotland.

Authors:  H Campbell; S Holloway; R Cetnarskyj; E Anderson; R Rush; A Fry; D Gorman; M Steel; M Porteous
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.